Laurus Labs shares hit a record high after Q2FY27 revenue rose 33% and net profit jumped 126%. The company declared an interim dividend and expanded peptide manufacturing. While brokerages recognized growth prospects, they urged investors to weigh potential against the stock’s sharp rally.